ArticleToxics2025
Machine Learning Framework for Multi-Endpoint Quantum Dot Toxicity Prediction with Organoid Validation and Drug Target Discovery.
Article in Toxics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Quantum dots (QDs) possess unique optical and electronic properties, enabling wide applications in biomedicine and optoelectronics, but their nanoscale size and surface chemistry could pose potential toxicity risks. This study established a systematic, multi-endpoint framework for QD toxicity assessment. Physicochemical properties of various QDs and their multiple toxicity endpoints, including cell death, inflammation, and oxidative stress, were collected to build machine learning models (RF, XGBoost, KNN, SVM). The predictive toxic effects were then validated based on the brain organoid. Shapley Additive exPlanations (SHAP) analysis revealed that exposure dose and particle size were key cross-model drivers, while zeta potential and optical properties differentially affected specific toxicity endpoints. Integration of GEO-derived differentially expressed genes with protein-protein interaction networks and molecular docking showed that the proteasome inhibitor Carfilzomib is an efficient interventive drug because of its strongest binding to core targets. In this study, the framework of prediction, validation and intervention effectively evaluated multi-endpoint QD toxicity and provided a systematic approach for safety assessments and strategy developments of nanomaterials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.